Suchergebnisse - "Bakris, George"

PubPharm (241)

1

RNA Interference With Zilebesiran for Mild to Moderate Hypertension : The KARDIA-1 Randomized Clinical Trial

enthalten in: JAMA | 2024

von Bakris, G. | Saxena, M. | Gupta, A. | +109

CommentIn: JAMA. 2024 Mar 5;331(9):733-735. - PMID 38363578

2

Resistant hypertension : cardiorenal protection with mineralocorticoid receptor blockade

enthalten in: European heart journal | 2024

von Pitt, B. | Bakris, G.

3

Association of uncontrolled blood pressure in apparent treatment-resistant hypertension with increased risk of major adverse cardiovascular events plus

enthalten in: Journal of clinical hypertension (Greenwich, Conn.) | 2023

von Bakris, G. | Chen, C. | Campbell, A. | +3

4

Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension

enthalten in: The New England journal of medicine | 2023

von Desai, A. | Webb, D. | Taubel, J. | +8

CommentIn: Nat Rev Cardiol. 2023 Oct;20(10):647. - PMID 37524808

5

Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease

enthalten in: Postgraduate medicine | 2023

von Lerma, E. | White, W. | Bakris, G.

6

Newer alternatives for resistant hypertension : Beyond 2022 paradigms

enthalten in: Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese | 2023

von Laffin, L. | Briasoulis, A. | Bakris, G.

7

Novel Therapies on the Horizon of Hypertension Management

enthalten in: American journal of hypertension | 2023

von Blazek, O. | Bakris, G.

8

Novel antihypertensive agents for resistant hypertension : what does the future hold?

enthalten in: Hypertension research : official journal of the Japanese Society of Hypertension | 2022

von Salvador, V. | Bakris, G.

9

Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION) : a multicentre, blinded, randomised, parallel-group, phase 3 trial

enthalten in: Lancet (London, England) | 2022

von Schlaich, M. | Bellet, M. | Weber, M. | +109

CommentIn: Lancet. 2022 Dec 3;400(10367):1900-1901. - PMID 36356630

10

Long-term outcomes after catheter-based renal artery denervation for resistant hypertension : final follow-up of the randomised SYMPLICITY HTN-3 Trial

enthalten in: Lancet (London, England) | 2022

von Bhatt, D. | Vaduganathan, M. | Kandzari, D. | +110

CommentIn: Lancet. 2022 Oct 22;400(10361):1382-1383. - PMID 36130611

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[25]